Comparative Pharmacology
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE versus DOBUTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE versus DOBUTREX.
DOBUTAMINE HYDROCHLORIDE vs DOBUTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dobutamine directly stimulates β1-adrenergic receptors in the heart, increasing myocardial contractility and stroke volume with minimal chronotropic effect at therapeutic doses. It also has mild β2 and α1 activity.
Dobutamine is a direct-acting inotropic agent primarily stimulating beta-1 adrenergic receptors, with mild beta-2 and alpha-1 effects. It increases myocardial contractility and stroke volume, resulting in increased cardiac output.
Intravenous infusion: 2.5-20 mcg/kg/min, titrated to hemodynamic response. Typical starting dose 2.5-5 mcg/kg/min.
2.5-20 mcg/kg/min continuous IV infusion; titrate to hemodynamic response.
None Documented
None Documented
2-3 minutes (short distribution half-life). Terminal elimination half-life is approximately 2 minutes. Clinical context: Requires continuous intravenous infusion for sustained effect due to rapid clearance.
Terminal elimination half-life approximately 2 minutes; clinical effects wane within minutes of infusion cessation due to rapid redistribution and metabolism
Primarily renal (90-95% as inactive metabolites, mainly glucuronide conjugates and 3-O-methyl metabolites). Less than 5% excreted unchanged. Biliary/fecal elimination is minimal (<5% in feces).
Renal: 75-80% as metabolites (3-O-methyl-dobutamine and conjugates) and unchanged drug; minor biliary/fecal elimination (<5%)
Category C
Category C
Inotropic Agent
Inotropic Agent